Global Multiple Myeloma Drugs Market 2017-2021

2016-12-27
Price :
Published : Dec-2016
No. of Pages : 86

Multiple myeloma is an abnormal growth and accumulation of plasma cells in the bone marrow leading to malignancy. This can be caused by the overproduction of monoclonal immunoglobulins such as IgG, IgA, IgD, or IgE; or Bence-Jones protein. Under normal conditions, stem cells develop into B lymphocytes, mature in the lymph nodes, and are transported throughout the body. On the entry of foreign substances into the body, these B-cells develop into plasma cells and produce immunoglobulins against the disease. However, in multiple myeloma, the B-cells are damaged and give rise to many malignant plasma cells that produce excessive immunoglobulins of a single type, which the body does not require.

The analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during the period 2017-2021.

Covered in this report

This report covers the present scenario and the growth prospects of the global multiple myeloma drugs market for 2017-2021. To calculate the market size, This report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent multiple myeloma.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Multiple Myeloma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Amgen
  • Celgene
  • Johnson & Johnson
  • Novartis
  • Takeda Pharmaceuticals

Other prominent vendors

  • AB Science
  • AbbVie
  • Acceleron Pharma
  • Acetylon Pharmaceuticals
  • Adaptimmune Therapeutics
  • Alexion Pharmaceuticals
  • AmpliMed Corporation
  • Array BioPharma
  • Benovus Bio
  • BioInvent
  • Biokine Therapeutics
  • Biotest
  • bluebird bio
  • Bristol-Meyer Squibb
  • Calithera Biosciences
  • CASI Pharmaceuticals
  • Celldex Therapeutics
  • Cellectar Biosciences
  • Chroma Therapeutics
  • Cleave Biosciences
  • Curis
  • Dicerna Pharmaceuticals
  • Eureka Therapeutics
  • F. Hoffmann-La Roche
  • Geron Corporation
  • GlycoMimetics
  • GlaxoSmithKline
  • ImmunoGen
  • Immunomedics
  • Innate Pharma
  • JW Pharmaceutical
  • Karyopharm Therapeutics
  • Kyowa Hakko Kirin
  • Merck
  • Midatech Pharma
  • Mirna Therapeutics
  • Molecular Partners
  • MorphoSys
  • NOXXON Pharma
  • Oncoceutics
  • Oncolytics Biotech
  • OncoPep
  • Oncopeptides
  • Ono Pharmaceutical
  • Otsuka Pharmaceuticals
  • Patrys
  • PharmaMar
  • Polyphor
  • Prothena Therapeutics
  • Sanofi
  • Sevion Therapeutics
  • Specialised Therapeutics
  • Spectrum Pharmaceutical
  • SymBio Pharmaceuticals
  • TaiGen Biotechnology
  • Tragara Pharmaceuticals
  • Vaxil Therapeutics
  • Vivolux

Market driver

  • Growing demand for biologic therapies
  • For a full, detailed list, view our report

Market challenge

  • Growing popularity of complementary and alternative medicines (CAM)
  • For a full, detailed list, view our report

Market trend

  • Emergence of nanomedicine platform
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : Technavio
More Reports
Title Price Buy Now

Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2018

Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Transdermal Drug Delivery currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transdermal Drug Delivery pipeline products. This report is prepared using data sourced from in-house databases, secondary......
$4000

Auto-Immune Diseases Diagnostic Tests – Medical Devices Pipeline Assessment, 2018

Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018" provides an overview of Auto-Immune Diseases Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Auto-Immune Diseases Diagnostic Tests pipeline products. This report is prepared using......
$4000

The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area

The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area Summary GlobalData's "The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area", provides an insight-rich overview of the key events and trends that our analysts expect to occur during 2018. This forward-looking view of the industry identifies key events that will occur across the major therapeutic areas - oncology, immunology, neurology, cardiovascular diseases, metabolic disorders, infectious diseases, and ophthalmology - and provides analyst insight on the potential ramifications of each event. 2018 promises to be a year of continued innovation in the biopharmaceutical industry across therapy areas. In this report, GlobalData's analysts highlight a selectio......
$500

Acne Vulgaris – Epidemiology Forecast to 2026

Acne Vulgaris - Epidemiology Forecast to 2026 Summary Acne vulgaris (acne) is a chronic inflammatory skin disease that presents as open or closed comedones and inflammatory lesions. Comedones include blackheads and whiteheads, while inflammatory lesions include papules, pustules, or cysts. Acne is a common skin disease that predominantly affects adolescents and young adults, but can also persist into adulthood. Mortality is not associated with acne, although major physical and psychological characteristics may develop, such as acne scarring, poor self-esteem, depression, and anxiety. The distribution of acne in the population is influenced by genetic background and dietary habits. For age- and sex-specific total prevalent cases, GlobalData epidemiologists utilized country-specific data ......
$3995

Dental Biomaterials – Medical Devices Pipeline Assessment, 2018

Dental Biomaterials - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Dental Biomaterials - Medical Devices Pipeline Assessment, 2018" provides an overview of Dental Biomaterials currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dental Biomaterials pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by......
$4000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Jordan

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Jordan Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Jordan". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Jordan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Jordan. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical market. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's......
$1995

PharmSource: Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2023

PharmSource: Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2023 Summary This report is the 6th edition of our long-running analysis of the injectables CMO industry. It provides an expert quantitative analysis on the latest trends and plans for outsourcing commercially approved injectable products. It combines the rich data resources of PharmSource and the GlobalData Pharmaceutical Intelligence Center with our 20 years' experience in analyzing the injectables CMO industry to provide the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm. Scope - The report is based on the most recent data on industry capacity, the injectables pipeline and the behaviors of the key biopharmaceutical industry actors. - Th......
$4995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Denmark

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Denmark Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Denmark". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Denmark. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis......
$1995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Sweden

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Sweden Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Sweden". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Sweden. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Sweden. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house anal......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the re......
$1000